Are Rapid-Acting Insulin Analogs Created Equal?


By: Daniel Trecroci

German researchers who compared insulin lispro (Humalog) and insulin aspart (NovoLog) report that the two insulins are equally effective in controlling after-meal blood glucose in people with type 1 diabetes.

In a study funded by Novo Nordisk—the maker of NovoLog—24 people with type 1 diabetes were observed in a single-center, randomized, double-blind trial. The participants were given Humalog or NovoLog injections immediately before a standard mixed meal.

Blood-glucose excursions 4 hours and 6 hours after the meal were equivalent, as were maximum blood-glucose excursions.

Diabetes Care, November 2002



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.